Long-term sotatercept treatment of pulmonary arterial hypertension: pooled analysis of efficacy and safety

Extract Sotatercept is a first-in-class activin-signalling inhibitor approved for treatment of pulmonary arterial hypertension (PAH) [1–3]. SOTERIA ( NCT07218029 ) is a phase III, single-arm, open-label, follow-up study assessing long-term safety, tolerability and efficacy of sotatercept in adults with PAH who participated in a parent sotatercept study [4]. Analysis of pooled data from time of SOTERIA entry through 1 year (mean 15 months) of treatment with sotatercept was previously reported [4]. Here, we provide a novel, more comprehensive and updated analysis of SOTERIA participants from the time of sotatercept initiation (during the parent study or, for those receiving placebo throughout the parent study, at rollover into SOTERIA) up to a median of 2.5 years.

Authors

Institutions

Publication Details

Journal
ERJ Open Research
Published
2026-11-12
DOI
https://doi.org/10.1183/23120541.01546-2026
Primary Topic
Pulmonary Hypertension Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Long-term sotatercept treatment of pulmonary arterial hypertension: pooled analysis of efficacy and safety

Ioana R. Preston, Marius M. Hoeper, Howard Martin Julien, Harald S. Mackenzie et al.
ERJ Open Research
Pulmonary Hypertension Research and Treatments
article

Long-term sotatercept treatment of pulmonary arterial hypertension: pooled analysis of efficacy and safety

Ioana R. Preston, Marius M. Hoeper, Howard Martin Julien, Harald S. Mackenzie, Aaron B. Waxman, Loı̈c Perchenet, J. Simon R. Gibbs, Mardi Gomberg‐Maitland, David B. Badesch, Vallerie V. McLaughlin, Marc J.C. Humbert, Hossein Ardeschir Ghofrani, James Strait, Alexandra G. Cornell, Barry Miller, Jianxin Lin, Yaru Shi, Rogerio Souza
article en

Abstract

Extract Sotatercept is a first-in-class activin-signalling inhibitor approved for treatment of pulmonary arterial hypertension (PAH) [1–3]. SOTERIA ( NCT07218029 ) is a phase III, single-arm, open-label, follow-up study assessing long-term safety, tolerability and efficacy of sotatercept in adults with PAH who participated in a parent sotatercept study [4]. Analysis of pooled data from time of SOTERIA entry through 1 year (mean 15 months) of treatment with sotatercept was previously reported [4]. Here, we provide a novel, more comprehensive and updated analysis of SOTERIA participants from the time of sotatercept initiation (during the parent study or, for those receiving placebo throughout the parent study, at rollover into SOTERIA) up to a median of 2.5 years.

ERJ Open Research
Brigham and Women's Hospital (US), Merck & Co., Inc., Rahway, NJ, USA (United States) (US), Lahey Hospital and Medical Center (US), Harvard University (US), Inserm (FR), George Washington University (US), Justus-Liebig-Universität Gießen (DE), Université Paris-Saclay (FR), University of Michigan (US), University of Colorado System (US), Medizinische Hochschule Hannover (DE), Assistance Publique – Hôpitaux de Paris (FR), Lahey Medical Center (US), German Center for Lung Research (DE), Universities of Giessen and Marburg Lung Center (DE), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (BR), Bicêtre Hospital (FR), Instituto do Coração - HCFMUSP (BR), Imperial College London (GB), University of Colorado Anschutz Medical Campus (US)
Good health and well-being
Pulmonary Hypertension Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon